Skip to main content
. 2022 Sep 24;22:18–33. doi: 10.1016/j.bioactmat.2022.09.015

Fig. 6.

Fig. 6

Evaluation of the ITGA5 antagonist AV3 in vitro and in silico. A) Schematic representation demonstrating the de-activation of PSCs to their quiescent phenotype by binding of AV3 to ITGA5 on activated PSCs resulting in the prevention of contraction. B) Outline of channels in PSC-laden Col/Fib gels treated with vehicle (DMSO), 20 μM or 50 μM AV3 followed for a total duration of 3 days (f.c. = fully closed). Scale bar = 500 μm. C) Contraction of channels in PSC-laden Col/Fib gels treated with vehicle (DMSO), 20 μM or 50 μM AV3 followed for a total duration of 3 days and standardized to the initial days, n = 3. Arrow indicates treatment with AV3. *indicates significant between vehicle and 50 μm AV3, #indicates significance between vehicle and 20 μm AV3. D) Contraction of channels in PSC-laden Col/Fib gels treated with vehicle (DMSO), 20 μM or 50 μM AV3 followed for a total duration of 3 days and standardized to the vehicle control, n = 3. E) Computational fluid dynamics (CFD) simulations of channels after treatment with vehicle or 50 μM AV3 depicting the pressure inside of the channel. F) CFD simulations of channels after treatment with vehicle or 50 μM AV3 depicting the flow velocity inside of the channel. Mean + SEM, */#p < 0.05, **p < 0.01, ***p < 0.001.